Introduce

Genetic Variants Screening for solid tumors diagnostics

NGeneBio’s ONCOaccuPanel™ is the next generation of sequencing (NGS) To establish diagnostic and treatment strategies and predict prognosis for patients with solid cancer. In vitro diagnostic medical device.
ONCOaccuPanel ™ is an Essential Gene for Health Notification by the Ministry of Health and Welfare It consists of 328 genes, including 14, that are specific to cancer patients in Korea. Analytical automation software is also provided for convenience in the field You can increase it.

Working Process

Specification

ONCOaccuPanel™
Useful Solid tumor
Technique NGS (Next Generation Sequencing)
Platforms Illumina, MiSeq, MiSeqDx, NextSeq 500/550. NextSeq 500/550 Dx
Target enrichments Capture based Hybridization
Sample Source FFPOE, blood
Sample type DNA, RNA
Quantity 96 samples (MiSeq system), 768 samples (NextSeq system)
Analysis solution NGeneAnalySys™
Target genes Total 328 genes
Target size 1.1 MB
Bariants type SNV, INDEL, CNV, SV, MSI, (TMB)
Turn around time 1.5 days

Performance

SNV, Indel mutation Translocation CNV
Target coverage TP TN/FN TP TN TP TN
234 2895/5 3 295 89 824
NextSeq results TP TN TP TN TP TN TP TN TP TN TP TN
23 1 5 28 3 0 0 29 86 3 3 821
3 94 5
Sensitivity 99.6% 100% 96.6%
Specificity 100% 100% 96.6%

Sensitivity = (next231+sanger2)/(miseq 232+sanger2) TP/(TP+FN) = 233/234 = 99.57%

Speccificity = (next2890+sanger4)/(miseq 2896+sanger4) TP/(TP+FN) = 2894/2900 = 99.79%

Information

Cat no. Products No. of samples

NGB121UWW

ONCOaccuPanel™

(Include library prep and enrichment reagents)
96 samples (MiSeq)
768 samples (NextSeq)